Graves‘ disease following vaccination against SARS-CoV-2: A systematic review of the reported cases
The newly developed COVID-19 vaccines have established a safe profile, yet some individuals experience a wide range of adverse events. Recently, thyroid dysfunction, including Graves’ disease, has been observed after administration of different COVID-19 vaccines, although causality remains a matter...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.938001/full |
| _version_ | 1818016451451158528 |
|---|---|
| author | Konstantinos Katsikas Triantafyllidis Konstantinos Katsikas Triantafyllidis Panagiotis Giannos Panagiotis Giannos Dimitra Stathi Dimitra Stathi Konstantinos S. Kechagias Konstantinos S. Kechagias |
| author_facet | Konstantinos Katsikas Triantafyllidis Konstantinos Katsikas Triantafyllidis Panagiotis Giannos Panagiotis Giannos Dimitra Stathi Dimitra Stathi Konstantinos S. Kechagias Konstantinos S. Kechagias |
| author_sort | Konstantinos Katsikas Triantafyllidis |
| collection | DOAJ |
| description | The newly developed COVID-19 vaccines have established a safe profile, yet some individuals experience a wide range of adverse events. Recently, thyroid dysfunction, including Graves’ disease, has been observed after administration of different COVID-19 vaccines, although causality remains a matter of debate. The aim of this systematic review was to examine the available literature and provide an overview of reported cases of Graves’ disease following COVID-19 vaccination. We identified 21 eligible articles which included 57 patients with Graves’ disease following COVID-19 vaccination. Fourteen participants were males (25%, 14/57) and 43 (75%, 44/57) were females with a mean age of 44.3 years. The most common presenting symptom was palpitations (63%, 27/43) followed by weight loss (35%, 15/43). The majority of patients received thionamides (47%, 25/53). The clinical status after treatment was provided for 37 patients and it was improved in the majority of them (84%, 31/37). Graves’ disease is possibly a condition clinicians may expect to encounter in patients receiving COVID-19 vaccines. While the above adverse event is rare, considering the scarcity of available data in scientific literature, and causality is not yet confirmed, the increased awareness of clinicians and the early recognition of the disorder are important for the optimal management of these patients. |
| first_indexed | 2024-04-14T07:12:32Z |
| format | Article |
| id | doaj.art-4d8d89e7d2c84af89962f7b451f111b8 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-14T07:12:32Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-4d8d89e7d2c84af89962f7b451f111b82022-12-22T02:06:23ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-09-011310.3389/fendo.2022.938001938001Graves‘ disease following vaccination against SARS-CoV-2: A systematic review of the reported casesKonstantinos Katsikas Triantafyllidis0Konstantinos Katsikas Triantafyllidis1Panagiotis Giannos2Panagiotis Giannos3Dimitra Stathi4Dimitra Stathi5Konstantinos S. Kechagias6Konstantinos S. Kechagias7Society of Meta-research and Biomedical Innovation, London, United KingdomDepartment of Nutrition and Dietetics, Homerton University Hospital Foundation Trust, London, United KingdomSociety of Meta-research and Biomedical Innovation, London, United KingdomDepartment of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, United KingdomSociety of Meta-research and Biomedical Innovation, London, United KingdomDepartment of Endocrinology and Diabetes, Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust, London, United KingdomSociety of Meta-research and Biomedical Innovation, London, United KingdomDepartment of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, United KingdomThe newly developed COVID-19 vaccines have established a safe profile, yet some individuals experience a wide range of adverse events. Recently, thyroid dysfunction, including Graves’ disease, has been observed after administration of different COVID-19 vaccines, although causality remains a matter of debate. The aim of this systematic review was to examine the available literature and provide an overview of reported cases of Graves’ disease following COVID-19 vaccination. We identified 21 eligible articles which included 57 patients with Graves’ disease following COVID-19 vaccination. Fourteen participants were males (25%, 14/57) and 43 (75%, 44/57) were females with a mean age of 44.3 years. The most common presenting symptom was palpitations (63%, 27/43) followed by weight loss (35%, 15/43). The majority of patients received thionamides (47%, 25/53). The clinical status after treatment was provided for 37 patients and it was improved in the majority of them (84%, 31/37). Graves’ disease is possibly a condition clinicians may expect to encounter in patients receiving COVID-19 vaccines. While the above adverse event is rare, considering the scarcity of available data in scientific literature, and causality is not yet confirmed, the increased awareness of clinicians and the early recognition of the disorder are important for the optimal management of these patients.https://www.frontiersin.org/articles/10.3389/fendo.2022.938001/fullGraves’ diseasethyroiditisCOVID-19SARS–CoV–2vaccines |
| spellingShingle | Konstantinos Katsikas Triantafyllidis Konstantinos Katsikas Triantafyllidis Panagiotis Giannos Panagiotis Giannos Dimitra Stathi Dimitra Stathi Konstantinos S. Kechagias Konstantinos S. Kechagias Graves‘ disease following vaccination against SARS-CoV-2: A systematic review of the reported cases Frontiers in Endocrinology Graves’ disease thyroiditis COVID-19 SARS–CoV–2 vaccines |
| title | Graves‘ disease following vaccination against SARS-CoV-2: A systematic review of the reported cases |
| title_full | Graves‘ disease following vaccination against SARS-CoV-2: A systematic review of the reported cases |
| title_fullStr | Graves‘ disease following vaccination against SARS-CoV-2: A systematic review of the reported cases |
| title_full_unstemmed | Graves‘ disease following vaccination against SARS-CoV-2: A systematic review of the reported cases |
| title_short | Graves‘ disease following vaccination against SARS-CoV-2: A systematic review of the reported cases |
| title_sort | graves disease following vaccination against sars cov 2 a systematic review of the reported cases |
| topic | Graves’ disease thyroiditis COVID-19 SARS–CoV–2 vaccines |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.938001/full |
| work_keys_str_mv | AT konstantinoskatsikastriantafyllidis gravesdiseasefollowingvaccinationagainstsarscov2asystematicreviewofthereportedcases AT konstantinoskatsikastriantafyllidis gravesdiseasefollowingvaccinationagainstsarscov2asystematicreviewofthereportedcases AT panagiotisgiannos gravesdiseasefollowingvaccinationagainstsarscov2asystematicreviewofthereportedcases AT panagiotisgiannos gravesdiseasefollowingvaccinationagainstsarscov2asystematicreviewofthereportedcases AT dimitrastathi gravesdiseasefollowingvaccinationagainstsarscov2asystematicreviewofthereportedcases AT dimitrastathi gravesdiseasefollowingvaccinationagainstsarscov2asystematicreviewofthereportedcases AT konstantinosskechagias gravesdiseasefollowingvaccinationagainstsarscov2asystematicreviewofthereportedcases AT konstantinosskechagias gravesdiseasefollowingvaccinationagainstsarscov2asystematicreviewofthereportedcases |